Because 4T1 breast cancer cells did not express IL9R on their surface (Supplementary Fig. S4), the therapeutic effect of IL9 therapy on macrophage-enriched 4T1 breast cancer was also evaluated (Fig. 6F–H). Here, IL9R is linked to breast carcinoma.